Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 7/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536614 | 0.93 | DUT (0.44) | DUTDDB1CRBNCYP19A1ALDH1A1 | |
| SCHEMBL21536737 | 0.91 | DUT (0.45) | DUTCYP19A1MAPTMEN1ALDH1A1 | |
| SCHEMBL20204892 | 0.86 | DUT (0.47) | DUTDDB1CRBNCYP19A1MAPT | |
| SCHEMBL21536070 | 0.83 | DUT (0.46) | DUTCYP19A1ALDH1A1POLBKMT2A | |
| SCHEMBL21536686 | 0.82 | DDB1 (0.43) | DUTDDB1CRBNALDH1A1PKM | |
| SCHEMBL21536067 | 0.82 | DDB1 (0.46) | DUTDDB1CRBNCYP19A1MAPT | |
| SCHEMBL21536072 | 0.81 | DUT (0.59) | DUT | |
| SCHEMBL24153933 | 0.80 | DUT (0.43) | DUTCYP19A1MAPTMEN1ALDH1A1 | |
| SCHEMBL21536579 | 0.79 | DUT (0.47) | DUTDDB1CRBNALDH1A1POLB | |
| SCHEMBL20204681 | 0.79 | KAT6A (0.54) | DUTCYP19A1MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-09 | — | — | US | disclosed |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| WO-2018098209-A1 | AMINO SULFONYL COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168059-B2 | Amino sulfonyl compounds | DPYD, DNPEP, DUT | DUT 3/4885DDB1 33/4885CRBN 1595/4885 |
| US-20190330158-A1 | AMINO SULFONYL COMPOUNDS | DPYD, DNPEP, DUT | DUT 3/4885DDB1 33/4885CRBN 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.